1. Home
  2. FORTY vs NUVB Comparison

FORTY vs NUVB Comparison

Compare FORTY & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FORTY

Formula Systems (1985) Ltd.

HOLD

Current Price

$108.00

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.78

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FORTY
NUVB
Founded
1985
2018
Country
Israel
United States
Employees
N/A
307
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
FORTY
NUVB
Price
$108.00
$5.78
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$11.38
AVG Volume (30 Days)
458.0
9.1M
Earning Date
05-21-2026
05-04-2026
Dividend Yield
1.32%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$203.82
Revenue Next Year
N/A
$58.18
P/E Ratio
$36.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$102.01
$2.18
52 Week High
$190.56
$9.75

Technical Indicators

Market Signals
Indicator
FORTY
NUVB
Relative Strength Index (RSI) 40.02 54.31
Support Level $101.61 $5.26
Resistance Level $134.92 $6.37
Average True Range (ATR) 0.92 0.36
MACD -0.14 -0.04
Stochastic Oscillator 29.96 47.09

Price Performance

Historical Comparison
FORTY
NUVB

About FORTY Formula Systems (1985) Ltd.

Formula Systems (1985) Ltd is an information technology company that is principally engaged through its directly and indirectly held investees in providing software consulting services, selling and marketing computer-based business solutions and hardware products from a wide range of domestic and international manufacturers, as well as developing proprietary software solutions. It delivers solutions in Israel and in numerous countries to customers with complex IT services needs. It designs and implements IT solutions and software systems that improve the productivity of customers' existing IT assets, enable them to effectively manage their operations and reduce their business risks in the face of changing business environments.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: